SPR Therapeutics, a Cleveland, Ohio firm, landed clearance from the FDA for its SPRINT endura and extensa peripheral percutaneous electric nerve stimulators (PENS). The endura is a single lead system, while the extensa is dual lead.
The two devices represent the only FDA cleared dual-lead capable percutaneous electrical nerve stimulators that that can be used for up to two months in either the back or the extremities, and for both acute and chronic pain.
The company believes that its technology can put a dent into the opioid epidemic by providing an affordable option, in many cases, to use the SPRINT PNS before the patient gets hooked on drugs.
The system uses a “MicroLead” that is delivered via a 20-gauge introducer, the proximal end of which is connected to a wearable controller device. The MicroLead has a barbed anchor to keep it in place, but the highly flexible coil of the lead allows the patient free movement with little discomfort.
Product page: SPRINT PNS System…
Via: SPR Therapeutics…